Cargando…

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells

Background: The management of Philadelphia Chromosome-positive (Ph+) hematological malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs). However, these drugs do not induce leukemic stem cells death and their persistence may generate a disease relapse. Publishe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massimino, Michele, Vigneri, Paolo, Stella, Stefania, Tirrò, Elena, Pennisi, Maria Stella, Parrinello, Laura Nunziatina, Vetro, Calogero, Manzella, Livia, Stagno, Fabio, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658323/ https://www.ncbi.nlm.nih.gov/pubmed/34884309 http://dx.doi.org/10.3390/jcm10235606

Ejemplares similares

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
por: Massimino, Michele, et al.
Publicado: (2023)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
por: Massimino, Michele, et al.
Publicado: (2018)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy
por: Vigneri, Paolo Giovanni, et al.
Publicado: (2015)

New Insights in Thyroid Cancer and p53 Family Proteins
por: Manzella, Livia, et al.
Publicado: (2017)

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023)

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
por: Stella, Stefania, et al.
Publicado: (2021)

Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
por: Stella, Stefania, et al.
Publicado: (2022)

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
por: Stella, Stefania, et al.
Publicado: (2021)

Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
por: Tirrò, Elena, et al.
Publicado: (2021)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
por: Manzella, Livia, et al.
Publicado: (2019)

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
por: Tirrò, Elena, et al.
Publicado: (2019)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
por: Romano, Chiara, et al.
Publicado: (2021)

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
por: Pennisi, Maria Stella, et al.
Publicado: (2023)

Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
por: Stella, Stefania, et al.
Publicado: (2023)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias
por: Stella, Stefania, et al.
Publicado: (2019)

Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
por: Massimino, Michele, et al.
Publicado: (2023)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
por: Wu, L. X., et al.
Publicado: (2020)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia
por: Zhang, Zhanglin, et al.
Publicado: (2019)

Insulin Receptor Isoforms Differently Regulate Cell Proliferation and Apoptosis in the Ligand-Occupied and Unoccupied State
por: Massimino, Michele, et al.
Publicado: (2021)

A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy
por: Liu, X, et al.
Publicado: (2017)

The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities
por: Stella, Stefania, et al.
Publicado: (2021)

A case of high‐risk AML in a patient with advanced systemic mastocytosis
por: Fazio, Manlio, et al.
Publicado: (2023)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques
por: Recchia, Anna Grazia, et al.
Publicado: (2015)

Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation
por: Shinohara, Haruka, et al.
Publicado: (2019)

SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells
por: Barbarani, Gloria, et al.
Publicado: (2019)

EFFECT OF THAI SARAPHI FLOWER EXTRACTS ON WT1 AND BCR/ABL PROTEIN EXPRESSION IN LEUKEMIC CELL LINES
por: Sangkaruk, Rungkarn, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review
por: Al Hamad, Mohammad
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h0ri32s5ertfb7m4aknjvso886